SEC Info - Sanofi - ‘6-K’ for 4/28/17

SEC Info℠

Home

Help

Please Sign In

Sanofi – ‘6-K’ for 4/28/17

On: Friday, 4/28/17, at 9:18am ET · For: 4/28/17 · Accession #: 1193125-17-145587 · File #: 1-31368

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 4/28/17  Sanofi                            6-K         4/28/17    4:73K                                    Donnelley … Solutions/FA

Report by a Foreign Private Issuer — Form 6-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Report by a Foreign Private Issuer                  HTML     13K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     11K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML     20K 
 4: EX-99.3     Miscellaneous Exhibit                               HTML     18K

6-K — Report by a Foreign Private Issuer

This is an HTML Document rendered as filed. [ Alternative Formats ]

6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2017

Commission File Number: 001-31368

SANOFI

(Translation of registrant’s name into English)

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

In April 2017, Sanofi issued the press releases attached hereto as Exhibit 99.1, 99.2 and 99.3 which are incorporated herein by reference.

Exhibit List


Exhibit No.		Description

Exhibit 99.1 Exhibit 99.2 Exhibit 99.3		Press release dated April 5, 2017: Sanofi Appoints Bill Sibold Executive Vice President Sanofi Genzyme and Member of the Executive Committee Press release dated April 24, 2017: Sanofi and Regeneron Receive CHMP Positive Opinion for Kevzara^® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Press release dated April 28, 2017: Sanofi and Regeneron Announce Kevzara^® (sarilumab) Biologics License Application Resubmission Accepted for Review by US FDA

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Dated: April 28, 2017			SANOFI

	By	/s/ *Alexandra Roger*
		Name:	Alexandra Roger
		Title:	Head of Securities Law and Capital Markets

Exhibit Index


Exhibit No.		Description
Exhibit 99.1		Press release dated April 5, 2017: Sanofi Appoints Bill Sibold Executive Vice President Sanofi Genzyme and Member of the Executive Committee

Exhibit 99.2		Press release dated April 24, 2017: Sanofi and Regeneron Receive CHMP Positive Opinion for Kevzara^® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis

Exhibit 99.3		Press release dated April 28, 2017: Sanofi and Regeneron Announce Kevzara^® (sarilumab) Biologics License Application Resubmission Accepted for Review by US FDA

Dates Referenced Herein and Documents Incorporated by Reference

This ‘6-K’ Filing	Date	Other Filings

Filed on / For Period End:	4/28/17	None on these Dates
	4/24/17
	4/5/17
		List all Filings

↑Top

Filing Submission 0001193125-17-145587 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)